Nooms proposed High-Priced Drug List would allow for compounded GLP-1s to be prescribed even in the absence of a drug shortage all in the name of lowering costs for consumers
Similarly, ophthalmological endpoints were investigated adjusting for (1) papilledema degree, (2) pRNFL thickness, (3) GCL volume, or (3) ONSD at baseline as appropriate and in a second step also for weight loss to evaluate potential independent treatment effects of GLP-1-RAs
The bottom line: a powerful tool, used the right way So who are these drugs for
Drug companies are cracking down on compounding pharmacies, but some apparently still provide the drug
Consistent monitoring of patients, especially during beginning and dosage escalation, is crucial for achieving good safety results
The American Journal of Clinical Nutrition, 104(2), 362370